乐普医疗注射用重组A型肉毒毒素获临床试验批准

Core Viewpoint - Lepu Medical announced that its subsidiary, Lepu Jiantang Pharmaceutical (Chongqing) Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of its self-developed recombinant type A botulinum toxin [1] Company Summary - The recombinant type A botulinum toxin is indicated for the temporary improvement of moderate to severe frown lines caused by the activity of the corrugator and/or depressor anguli oris muscles in adults aged 65 and below [1] - Botulinum toxin is widely used in the fields of facial and neck wrinkle removal and contour shaping, causing muscle relaxation and inhibiting gland secretion through its chemical denervation effects [1]